Literature DB >> 19652402

Anti human immunodeficiency virus-1 (HIV-1) agents 3. synthesis and in vitro anti-HIV-1 activity of some N-arylsulfonylindoles.

Ling-Ling Fan1, Wu-Qing Liu, Hui Xu, Liu-Meng Yang, Min Lv, Yong-Tang Zheng.   

Abstract

In order to find compounds with superior anti human immunodeficiency virus type 1 (HIV-1) activity, twelve simple N-arylsulfonylindoles (3a-l) were synthesized and preliminarily evaluated as HIV-1 inhibitors in vitro for the first time. Several compounds demonstrated significant anti-HIV-1 activity, especially N-(3-nitrobenzene)sulfonyl-6-methylindole (3h) and N-(3-nitrobenzene)sulfonylindole (3i) showed the highest anti-HIV-1 activity with EC(50) values of 0.26 and 0.74 microg/ml, and TI values of 543.78 and >270.27, respectively.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19652402     DOI： 10.1248/cpb.57.797

Source DB:  PubMed          Journal:  Chem Pharm Bull (Tokyo)        ISSN： 0009-2363            Impact factor:   1.645


  4 in total

1.  Synthesis of benzopyrano[4,3-b](N-arylsulfonyl)indoles and benzopyrano[3,4-b](N-arylsulfonyl)indoles via intramolecular palladium-catalyzed aryl-aryl coupling reaction.

Authors:  Ling-Ling Fan; Zhi-Ping Che; Rui Zhang; Xiang Yu; Xiao-Yan Zhi; Hui Xu
Journal:  Mol Divers       Date:  2012-04-22       Impact factor: 2.943

2.  Design and Synthesis of Novel N-Arylsulfonyl-3-(2-yl-ethanone)-6-methylindole Derivatives as Inhibitors of HIV-1 Replication.

Authors:  Zhiping Che; Shengming Liu; Yuee Tian; Zhenjie Hu; Yingwu Chen; Genqiang Chen
Journal:  Pharmaceuticals (Basel)       Date:  2015-05-08

3.  Synthesis and Bioactivity Evaluation of N-Arylsulfonylindole Analogs Bearing a Rhodanine Moiety as Antibacterial Agents.

Authors:  Ming-Xia Song; Song-Hui Li; Jiao-Yang Peng; Ting-Ting Guo; Wen-Hui Xu; Shao-Feng Xiong; Xian-Qing Deng
Journal:  Molecules       Date:  2017-06-14       Impact factor: 4.411

4.  Examination of novel 4-aminoquinoline derivatives designed and synthesized by a hybrid pharmacophore approach to enhance their anticancer activities.

Authors:  V Raja Solomon; Sheetal Pundir; Hoyun Lee
Journal:  Sci Rep       Date:  2019-04-19       Impact factor: 4.379
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.